JPMorgan Chase & Co. Buys 83,473 Shares of PetMed Express, Inc. (NASDAQ:PETS)

JPMorgan Chase & Co. grew its stake in PetMed Express, Inc. (NASDAQ:PETS) by 355.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 106,954 shares of the company’s stock after buying an additional 83,473 shares during the period. JPMorgan Chase & Co.’s holdings in PetMed Express were worth $516,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of PetMed Express during the fourth quarter worth $31,000. Virtu Financial LLC bought a new stake in PetMed Express during the fourth quarter valued at $58,000. Finally, American Century Companies Inc. grew its holdings in PetMed Express by 15.3% during the 4th quarter. American Century Companies Inc. now owns 33,662 shares of the company’s stock worth $162,000 after acquiring an additional 4,459 shares during the period. 73.33% of the stock is currently owned by institutional investors.

PetMed Express Stock Down 1.7 %

Shares of NASDAQ:PETS opened at $3.38 on Thursday. PetMed Express, Inc. has a twelve month low of $2.90 and a twelve month high of $6.85. The stock’s 50 day moving average is $3.76 and its 200-day moving average is $4.45. The firm has a market capitalization of $69.82 million, a price-to-earnings ratio of 338.34 and a beta of 0.99.

PetMed Express (NASDAQ:PETS) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. Equities research analysts anticipate that PetMed Express, Inc. will post 0.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PETS. Morgan Stanley cut their target price on PetMed Express from $3.50 to $3.20 and set an “underweight” rating on the stock in a research report on Thursday, April 17th. StockNews.com downgraded shares of PetMed Express from a “buy” rating to a “hold” rating in a research report on Wednesday, April 23rd.

PetMed Express Company Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.